康方生物(09926)早盘涨近5%，截至发稿，涨4.22%，报106.2港元，成交额4.56亿港元。 据悉，康方生物的曼多奇单抗是其进入上市申报阶段的第四款非肿瘤药物，此前PCSK9单抗伊努西单 抗、IL-12/IL-23单抗依若奇单抗、IL-17A单抗古莫奇单抗已相继获批或申报上市，构建了覆盖心血管代 谢、皮肤、关节等多领域的自免产品矩阵。 消息面上，2月25日，康方生物自主研发的IL-4Rα单抗(曼多奇单抗，AK120)已正式向国家药品监督管 理局(NMPA)提交上市申请(NDA)并获受理，拟用于治疗中重度特应性皮炎(AD)。 ...

据悉，康方生物的曼多奇单抗是其进入上市申报阶段的第四款非肿瘤药物，此前PCSK9单抗伊努西单 抗、IL-12/IL-23单抗依若奇单抗、IL-17A单抗古莫奇单抗已相继获批或申报上市，构建了覆盖心血管代 谢、皮肤、关节等多领域的自免产品矩阵。 智通财经APP获悉，康方生物(09926)早盘涨近5%，截至发稿，涨4.22%，报106.2港元，成交额4.56亿港 元。 消息面上，2月25日，康方生物自主研发的IL-4Rα单抗(曼多奇单抗，AK120)已正式向国家药品监督管 理局(NMPA)提交上市申请(NDA)并获受理，拟用于治疗中重度特应性皮炎(AD)。 ...

Core Insights - The article discusses the competitive landscape of the IL-4Rα monoclonal antibody market, highlighting Dupixent's dominance and the emerging challenges from new entrants [2][11][15] Group 1: Dupixent's Market Position - Dupixent, developed by Sanofi, has achieved significant sales milestones, with Q4 2025 revenue reaching €4.246 billion (approximately $5.085 billion), marking a 32.2% year-over-year increase [1] - Since its FDA approval in March 2017, Dupixent has rapidly become a leading drug in the autoimmune space, with sales surpassing $2.2 billion in its first year and exceeding $2 billion in 2019 [3][5] - The drug's success is attributed to its strategic targeting of the IL-4Rα pathway, which is crucial in mediating type 2 inflammation, and its innovative VelocImmune® technology that enhances safety and efficacy [6][7] Group 2: Competitive Landscape - The approval of Connoa's Suplizumab in September 2024 marks the second IL-4Rα monoclonal antibody to enter the market, intensifying competition against Dupixent [12] - Other candidates, including Leideqi (CBP-201) and Tairiqi, are in the NDA stage, indicating a growing pipeline of competitors that could challenge Dupixent's market share [13][14] - The emergence of these new IL-4Rα monoclonal antibodies suggests a shift from a "one-player" market to a more competitive environment, with multiple players vying for market share [11][15] Group 3: Future Outlook - The article suggests that while Dupixent remains a strong player, its growth may face challenges due to the increasing number of competitors and the saturation of its core indications [15] - The competitive dynamics in the IL-4Rα space are expected to evolve, with a focus on differentiation strategies and the expansion of indications being critical for maintaining market position [15]

智通财经APP获悉，康方生物(09926)涨超5%，截至发稿，涨5.16%，报118.1港元，成交2.31亿港元。 据介绍，古莫奇单抗是康方生物继伊努西单抗(PCSK9)、依若奇单抗(IL-12/IL-23)之后，第三个进入上 市阶段的非肿瘤重磅产品。随着伊努西单抗、依若奇单抗相继上市并纳入国家医保目录，古莫奇单抗、 曼多奇单抗等产品逐步迈入商业化阶段，以及IL-4R/ST2双抗、神经退行性病变等非肿瘤创新靶点药物 针对多适应症深度开发的高效推进，公司产品组合力愈发强劲，非肿瘤板块的竞争力持续增强。 消息面上，据康方生物官微消息，近日，公司宣布，其自主研发的新型人源化抗IL-17A单克隆抗体古莫 奇单抗(AK111)用于治疗活动性强直性脊柱炎(AS)的新药上市申请(sNDA)，已获得国家药品监督管理局 药品审评中心(NMPA CDE)受理。这标志着该药有望为中国近400万AS患者带来新的治疗选择。 ...

Core Viewpoint - Kangfang Biopharma reported a revenue of 1.412 billion yuan for the first half of 2025, marking a year-on-year increase of 37.75%, while the loss expanded to 588 million yuan from 249 million yuan in the same period last year [1][3] Financial Performance - Revenue for the period was 1.412 billion yuan, a 37.75% increase year-on-year [1] - Commercial sales revenue reached 1.402 billion yuan, up 49.20% year-on-year [1] - The company incurred a loss of 588 million yuan, which is an increase from the previous year's loss of 249 million yuan [1][3] Revenue Drivers - The growth in commercial sales revenue was primarily driven by the inclusion of AK104 and AK112 in the national medical insurance since January, leading to increased sales volume [1] - The increase in losses was attributed to a rise in equity investment losses from a partnership with Summit, which increased from 32.6 million yuan to 192 million yuan, as well as higher R&D expenses and stock incentive costs [3] Product Pipeline and Market Position - Kangfang Biopharma has received approval for seven products, including AK104 and AK112, which are key dual antibodies, and has expanded its commercial product range to include metabolic and autoimmune areas [4] - The sales team has grown from over 800 to 1,200 members, covering oncology and specialty drug sectors [4] - The company is focusing on AK112, which has shown promising results in clinical trials for non-small cell lung cancer [5][8] Clinical Development and Strategy - AK112 has achieved significant clinical endpoints in trials, including a statistically significant improvement in progression-free survival (PFS) [8][9] - The company is pursuing a strategy termed "IO2.0+ADC2.0," which aims to integrate dual antibodies with antibody-drug conjugates (ADCs) [12][13] - Kangfang Biopharma's pipeline includes ongoing clinical trials for various indications, with a focus on enhancing the efficacy of existing treatments [12][16]